Drugs / acylated ghrelin
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT00139945 | Oct 2005 → Mar 2007 | hypopituitarism | University of Aarhus | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | acylated ghrelin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00139945 ↗ |
| Action | Activate | “Our results support the hypothesis that pharmacological levels of acylated ghrelin directly activate lipolysis at the whole-body level.” PMID 32975853 ↗ Aug 2020 |
| Modality | Peptide | “Ghrelin is a gut-derived peptide and an endogenous ligand for the growth hormone (GH) secretagogue receptor.” PMID 18776138 ↗ Sep 2008 |